Caplin Point Laboratories share price
You have to be logged in to add this to Watchlist.- ₹2,018.20(-1.17%)July 11, 2025 15:28:00 PM IST
- NSE
- BSE
- Vol : 37.62K (NSE + BSE)Last 20 day avg : 104.32 K
Caplin Point Laboratories is trading -1.17% lower at Rs 2,018.20 as compared to its last closing price. Caplin Point Laboratories has been trading in the price range of 2,051.00 & 2,015.50. Caplin Point Laboratories has given -18.32% in this year & 2.00% in the last 5 days. Caplin Point Laboratories has TTM P/E ratio 28.34 as compared to the sector P/E of 22.90.There are 2 analysts who have initiated coverage on Caplin Point Laboratories. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 142.57 Crores in its last quarter.Listed peers of Caplin Point Laboratories include Jubilant Pharmova (-1.16%), Natco Pharma (-3.65%), Caplin Point Laboratories (-1.17%).The Mutual Fund holding in Caplin Point Laboratories was at 1.74% in 31 Mar 2025. The MF holding has decreased from the last quarter. The FII holding in Caplin Point Laboratories was at 5.70% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 12, 2025, 01:34 AM UTC
- Dividend YieldLower than industry0.15Annual dividends as a percentage of the stock price.
- P/BHigher than historical values5.38The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values28.69Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.55Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 10.86% from Rs 502.45 crore to Rs 453.22 crore, year-on-year
- The company has grown its March quarter profit by 17.25% from Rs 121.59 crore to Rs 142.57 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,206.43
- R2
- 2,296.12
- R3
- 2,422.23
- S1
- 1,990.63
- S2
- 1,864.52
- S3
- 1,774.83
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova | Neutral | 1,156.90 | -1.16 | 18,427.23 | 35.82 | 3.04 | 0.42 | 38.19 |
| Natco Pharma | Moderately Bullish | 961.75 | -3.65 | 17,225.89 | 9.25 | 2.29 | 0.62 | 0.06 |
| Caplin Point Laboratories | Moderately Bearish | 2,018.20 | -1.17 | 15,394.47 | 28.50 | 5.33 | 0.27 | 0.10 |
| Sanofi India | Moderately Bearish | 5,920.65 | -1.40 | 13,609.52 | 41.21 | 16.32 | 1.92 | 1.63 |
| Alivus Life Sciences | Bearish | 1,011.00 | -0.83 | 12,400.28 | 26.14 | 4.49 | - | 1.81 |
- Promoter(s) holds a high stake in the company at 70.56%
- FIIs are invested in this company
- FIIs holding has increased by 0.86 percentage points from previous quarter
Mutual Funds holding has decreased by 0.12 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-15 | Audited Results & Interim Dividend |
| 2025-02-07 | Quarterly Results |
| 2024-11-07 | Quarterly Results |
| 2024-08-07 | Quarterly Results & Final Dividend |
| 2024-05-16 | Audited Results & Interim Dividend |
- IndustryBiotechnology & Drugs
- ISININE475E01026
- BSE Code524742
- NSE CodeCAPLIPOINT
Caplin Point Laboratories is trading at 2018.20 as on Fri Jul 11 2025 09:58:00. This is -1.17% lower as compared to its previous closing price of 2042.05.
The market capitalization of Caplin Point Laboratories is 15394.47 Cr as on Fri Jul 11 2025 09:58:00.
The 52 wk high for Caplin Point Laboratories is 2636.00 whereas the 52 wk low is 1407.40
Caplin Point Laboratories can be analyzed on the following key metrics -
- TTM P/E: 28.34
- Sector P/E: 22.90
- Dividend Yield: 0.15%
- D/E ratio: 0.00
Caplin Point Laboratories reported a net profit of 536.31 Cr in 2025.
The Mutual Fund Shareholding was 1.74% at the end of 31 Mar 2025.